An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910